Executive Managing Director
Pierre Beauparlant, Ph.D. is the Executive Managing Director of Finchley Healthcare Ventures (FHV), a North American venture capital fund focused on investing in emerging private companies developing innovative therapies aimed at addressing significant unmet medical needs. Prior to joining FHV, Pierre was a Venture Partner at Sanderling Ventures, one of the pioneering life sciences venture capital firms in the San Francisco Bay Area. During his tenure, he also served as CEO of several portfolio companies, including PreciThera Inc., an early-stage biotech company specializing in biologics for rare musculoskeletal disorders, and SpecificiT Pharma Inc., a clinical-stage company advancing cellular therapies for cancer. Earlier in his career, Pierre held the role of Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals and before that, he held progressively senior roles at Gemin X Pharmaceuticals Inc., a venture-backed oncology company acquired by Cephalon in 2011. As Vice President of Research and Scientific Development, he was responsible for drug discovery, business development, in-licensing, and intellectual property strategy. Dr. Beauparlant earned his Ph.D. in Microbiology and Immunology from McGill University.